Cholesterol accumulation in prostate cancer: A classic observation from a modern perspective

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1835, Issue 2, 2013, Pages 219-229

  Krycer, James Robert ^a   Brown, Andrew John ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Androgen receptor; Cholesterol; Liver X receptor; Prostate cancer; Sterol regulatory element binding protein

Indexed keywords

BICALUTAMIDE; CHOLESTEROL; DOCETAXEL; LIVER X RECEPTOR; SIPULEUCEL T; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANDROGEN DEPRIVATION THERAPY; CANCER GROWTH; CANCER RISK; CELL GROWTH; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; DISEASE ASSOCIATION; GENETIC MANIPULATION; HOMEOSTASIS; HUMAN; LIPID STORAGE; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION;

CELL PROLIFERATION; CHOLESTEROL; HOMEOSTASIS; HUMANS; MALE; ORPHAN NUCLEAR RECEPTORS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

EID: 84873716248     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2013.01.002     Document Type: Review

References (178)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Schaffner C.P. Prostatic cholesterol metabolism: regulation and alteration. Prog. Clin. Biol. Res. 1981, 75A:279-324.
3. White C. On the occurence of crystals in tumours. J. Pathol. Bacteriol. 1909, 13:3-10.
4. Webb J.H. Cancer, its nature and treatment. Lancet 1901, ii:976.
5. Ohvo-Rekila H., Ramstedt B., Leppimaki P., Slotte J.P. Cholesterol interactions with phospholipids in membranes. Prog. Lipid Res. 2002, 41:66-97.
6. Simons K., Ikonen E. Functional rafts in cell membranes. Nature 1997, 387:569-572.
7. Brown A.J. Cholesterol, statins and cancer. Clin. Exp. Pharmacol. Physiol. 2007, 34:135-141.
8. Haenszel W., Kurihara M. Studies of Japanese migrants. I. Mortality from cancer and other diseases among Japanese in the United States. J. Natl. Cancer Inst. 1968, 40:43-68.
9. Shimizu H., Ross R.K., Bernstein L., Yatani R., Henderson B.E., Mack T.M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. Br. J. Cancer 1991, 63:963-966.
10. Solomon K.R., Freeman M.R. The complex interplay between cholesterol and prostate malignancy. Urol. Clin. North Am. 2011, 38:243-259.
11. Pelton K., Freeman M.R., Solomon K.R. Cholesterol and prostate cancer. Curr. Opin. Pharmacol. 2012, 12:751-759.
12. Bravi F., Scotti L., Bosetti C., Talamini R., Negri E., Montella M., Franceschi S., La Vecchia C. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann. Oncol. 2006, 17:1014-1017.
13. Platz E.A., Clinton S.K., Giovannucci E. Association between plasma cholesterol and prostate cancer in the PSA era. Int. J. Cancer 2008, 123:1693-1698.
14. Platz E.A., Leitzmann M.F., Visvanathan K., Rimm E.B., Stampfer M.J., Willett W.C., Giovannucci E. Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 2006, 98:1819-1825.
15. Murtola T.J., Tammela T.L., Lahtela J., Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 2007, 16:2226-2232.
16. Zhuang L., Lin J., Lu M.L., Solomon K.R., Freeman M.R. Cholesterol-rich lipid rafts mediate Akt-regulated survival in prostate cancer cells. Cancer Res. 2002, 62:2227-2231.
17. Solomon K.R., Pelton K., Boucher K., Joo J., Tully C., Zurakowski D., Schaffner C.P., Kim J., Freeman M.R. Ezetimibe is an inhibitor of tumor angiogenesis. Am. J. Pathol. 2009, 174:1017-1026.
18. Llaverias G., Danilo C., Wang Y., Witkiewicz A.K., Daumer K., Lisanti M.P., Frank P.G. A Western-type diet accelerates tumor progression in an autochthonous mouse model of prostate cancer. Am. J. Pathol. 2010, 177:3180-3191.
19. Swyer G.I.M. The cholesterol content of normal and enlarged prostates. Cancer Res. 1942, 2:372-375.
20. Olson R.E. Discovery of the lipoproteins, their role in fat transport and their significance as risk factors. J. Nutr. 1998, 128:439S-443S.
21. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
22. Bloch K. The biological synthesis of cholesterol. Science 1965, 150:19-28.
23. Endo A. A gift from nature: the birth of the statins. Nat. Med. 2008, 14:1050-1052.
24. Brown M.S., Goldstein J.L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 1980, 21:505-517.
25. Oram J.F., Vaughan A.M. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ. Res. 2006, 99:1031-1043.
26. Fukuchi J., Hiipakka R.A., Kokontis J.M., Hsu S., Ko A.L., Fitzgerald M.L., Liao S. Androgenic suppression of ATP-binding cassette transporter A1 expression in LNCaP human prostate cancer cells. Cancer Res. 2004, 64:7682-7685.
27. Pommier A.J., Alves G., Viennois E., Bernard S., Communal Y., Sion B., Marceau G., Damon C., Mouzat K., Caira F., Baron S., Lobaccaro J.M. Liver X receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells. Oncogene 2010, 29:2712-2723.
28. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002, 109:1125-1131.
29. Brown M.S., Goldstein J.L. Cholesterol feedback: from Schoenheimer's bottle to Scap's MELADL. J. Lipid Res. 2009, (50 Suppl.):S15-S27.
30. Amemiya-Kudo M., Shimano H., Hasty A.H., Yahagi N., Yoshikawa T., Matsuzaka T., Okazaki H., Tamura Y., Iizuka Y., Ohashi K., Osuga J.-i., Harada K., Gotoda T., Sato R., Kimura S., Ishibashi S., Yamada N. Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J. Lipid Res. 2002, 43:1220-1235.
31. Horton J.D., Shah N.A., Warrington J.A., Anderson N.N., Park S.W., Brown M.S., Goldstein J.L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:12027-12032.
32. Radhakrishnan A., Ikeda Y., Kwon H.J., Brown M.S., Goldstein J.L. Sterol-regulated transport of SREBPs from endoplasmic reticulum to Golgi: oxysterols block transport by binding to Insig. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:6511-6518.
33. Apfel R., Benbrook D., Lernhardt E., Ortiz M.A., Salbert G., Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell. Biol. 1994, 14:7025-7035.
34. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 1995, 9:1033-1045.
35. Teboul M., Enmark E., Li Q., Wikstrom A.C., Pelto-Huikko M., Gustafsson J.A. OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:2096-2100.
36. Song C., Kokontis J.M., Hiipakka R.A., Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:10809-10813.
37. Wu C., Orozco C., Boyer J., Leglise M., Goodale J., Batalov S., Hodge C.L., Haase J., Janes J., Huss J.W., Su A.I. BioGPS: an extensible and customizable portal for querying and organizing gene annotation resources. Genome Biol. 2009, 10:R130.
38. Su A.I., Wiltshire T., Batalov S., Lapp H., Ching K.A., Block D., Zhang J., Soden R., Hayakawa M., Kreiman G., Cooke M.P., Walker J.R., Hogenesch J.B. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6062-6067.
39. Lattin J.E., Schroder K., Su A.I., Walker J.R., Zhang J., Wiltshire T., Saijo K., Glass C.K., Hume D.A., Kellie S., Sweet M.J. Expression analysis of G protein-coupled receptors in mouse macrophages. Immunol. Res. 2008, 4:5.
40. Hu X., Li S., Wu J., Xia C., Lala D.S. Liver X receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 2003, 17:1019-1026.
41. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature 1996, 383:728-731.
42. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 1997, 272:3137-3140.
43. Glass C.K., Rosenfeld M.G. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000, 14:121-141.
44. Tall A.R., Costet P., Wang N. Regulation and mechanisms of macrophage cholesterol efflux. J. Clin. Invest. 2002, 110:899-904.
45. Zelcer N., Hong C., Boyadjian R., Tontonoz P. LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 2009, 325:100-104.
46. Du X., Kristiana I., Wong J., Brown A.J. Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis. Mol. Biol. Cell 2006, 17:2735-2745.
47. Luu W., Sharpe L.J., Stevenson J., Brown A.J. Akt acutely activates the cholesterogenic transcription factor SREBP-2. Biochim. Biophys. Acta 2012, 1823:458-464.
48. Krycer J.R., Sharpe L.J., Luu W., Brown A.J. The Akt-SREBP nexus: cell signaling meets lipid metabolism. Trends Endocrinol. Metab. 2010, 21:268-276.
49. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 2004, 25:276-308.
50. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1:34-45.
51. Horton R. Sex steroid production and secretion in the male. Andrologia 1978, 10:183-194.
52. Dunn J.F., Nisula B.C., Rodbard D. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J. Clin. Endocrinol. Metab. 1981, 53:58-68.
53. Bruchovsky N., Wilson J.D. The intranuclear binding of testosterone and 5-alpha-androstan-17-beta-ol-3-one by rat prostate. J. Biol. Chem. 1968, 243:5953-5960.
54. Grover P.K., Odell W.D. Correlation of in vivo and in vitro activities of some naturally occurring androgens using a radioreceptor assay for 5alpha-dihydrotestosterone with rat prostate cytosol receptor protein. J. Steroid Biochem. 1975, 6:1373-1379.
55. Liao S., Liang T., Fang S., Castaneda E., Shao T.C. Steroid structure and androgenic activity. Specificities involved in the receptor binding and nuclear retention of various androgens. J. Biol. Chem. 1973, 248:6154-6162.
56. Massie C.E., Lynch A., Ramos-Montoya A., Boren J., Stark R., Fazli L., Warren A., Scott H., Madhu B., Sharma N., Bon H., Zecchini V., Smith D.M., Denicola G.M., Mathews N., Osborne M., Hadfield J., Macarthur S., Adryan B., Lyons S.K., Brindle K.M., Griffiths J., Gleave M.E., Rennie P.S., Neal D.E., Mills I.G. The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO J. 2011, 30:2719-2733.
57. Huggins C., Clark P.J. Quantitative studies of prostatic secretion: II. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs. J. Exp. Med. 1940, 72:747-762.
58. Huggins C., Hodges C.V. Studies on prostatic cancer - I The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1:293-297.
59. Sharifi N., Gulley J.L., Dahut W.L. An update on androgen deprivation therapy for prostate cancer. Endocr. Relat. Cancer 2010, 17:R305-R315.
60. Akaza H. Combined androgen blockade for prostate cancer: review of efficacy, safety and cost-effectiveness. Cancer Sci. 2011, 102:51-56.
61. Schrijvers D. Androgen-independent prostate cancer. Recent Results Cancer Res. 2007, 175:239-249.
62. Petrylak D.P. New paradigms for advanced prostate cancer. Rev. Urol. 2007, 9(Suppl. 2):S3-S12.
63. Di Lorenzo G., Buonerba C., Autorino R., De Placido S., Sternberg C.N. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010, 70:983-1000.
64. Culig Z., Steiner H., Bartsch G., Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer 2005, 12:229-244.
65. Yuan X., Balk S.P. Mechanisms mediating androgen receptor reactivation after castration. Urol. Oncol. 2009, 27:36-41.
66. Mohler J.L. Castration-recurrent prostate cancer is not androgen-independent. Adv. Exp. Med. Biol. 2008, 617:223-234.
67. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
68. Leon C.G., Locke J.A., Adomat H.H., Etinger S.L., Twiddy A.L., Neumann R.D., Nelson C.C., Guns E.S., Wasan K.M. Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model. Prostate 2010, 70:390-400.
69. Mostaghel E.A., Solomon K.R., Pelton K., Freeman M.R., Montgomery R.B. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS One 2012, 7:e30062.
70. Sharifi N. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer. Expert Opin. Investig. Drugs 2010, 19:837-846.
71. Agarwal N., Hutson T.E., Vogelzang N.J., Sonpavde G. Abiraterone acetate: a promising drug for the treatment of castration-resistant prostate cancer. Future Oncol. 2010, 6:665-679.
72. Vis A.N., Schroder F.H. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 2009, 104:438-448.
73. Swinnen J.V., Van Veldhoven P.P., Esquenet M., Heyns W., Verhoeven G. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 1996, 137:4468-4474.
74. Swinnen J.V., Ulrix W., Heyns W., Verhoeven G. Coordinate regulation of lipogenic gene expression by androgens: evidence for a cascade mechanism involving sterol regulatory element binding proteins. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:12975-12980.
75. Heemers H., Maes B., Foufelle F., Heyns W., Verhoeven G., Swinnen J.V. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol. Endocrinol. 2001, 15:1817-1828.
76. Heemers H., Verrijdt G., Organe S., Claessens F., Heyns W., Verhoeven G., Swinnen J.V. Identification of an androgen response element in intron 8 of the sterol regulatory element-binding protein cleavage-activating protein gene allowing direct regulation by the androgen receptor. J. Biol. Chem. 2004, 279:30880-30887.
77. Krycer J.R., Brown A.J. Cross-talk between the androgen receptor and the liver X receptor: implications for cholesterol homeostasis. J. Biol. Chem. 2011, 286:20637-20647.
78. Lee J.H., Gong H., Khadem S., Lu Y., Gao X., Li S., Zhang J., Xie W. Androgen deprivation by activating the liver X receptor. Endocrinology 2008, 149:3778-3788.
79. Strott C.A. Sulfonation and molecular action. Endocr. Rev. 2002, 23:703-732.
80. Viennois E., Esposito T., Dufour J., Pommier A., Fabre S., Kemeny J.L., Guy L., Morel L., Lobaccaro J.M., Baron S. Lxralpha regulates the androgen response in prostate epithelium. Endocrinology 2012, 153:3211-3223.
81. Kim H.J., Andersson L.C., Bouton D., Warner M., Gustafsson J.A. Stromal growth and epithelial cell proliferation in ventral prostates of liver X receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:558-563.
82. Meyer M.E., Gronemeyer H., Turcotte B., Bocquel M.T., Tasset D., Chambon P. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell 1989, 57:433-442.
83. Hong C., Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr. Opin. Genet. Dev. 2008, 18:461-467.
84. Lee B.H., Taylor M.G., Robinet P., Smith J.D., Schweitzer J., Sehayek E., Falzarano S.M., Magi-Galluzzi C., Klein E.A., Ting A.H. Dysregulation of cholesterol homeostasis in human prostate cancer through loss of ABCA1. Cancer Res. 2013, 73:1211-1218.
85. Bonaccorsi L., Luciani P., Nesi G., Mannucci E., Deledda C., Dichiara F., Paglierani M., Rosati F., Masieri L., Serni S., Carini M., Proietti-Pannunzi L., Monti S., Forti G., Danza G., Serio M., Peri A. Androgen receptor regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. Lab. Invest. 2008, 88:1049-1056.
86. Zerenturk E.J., Kristiana I., Gill S., Brown A.J. The endogenous regulator 24(S),25-epoxycholesterol inhibits cholesterol synthesis at DHCR24 (Seladin-1). Biochim. Biophys. Acta 2012, 1821:1269-1277.
87. Krycer J.R., Kristiana I., Brown A.J. Cholesterol homeostasis in two commonly used human prostate cancer cell-lines, LNCaP and PC-3. PLoS One 2009, 4:e8496.
88. Horoszewicz J.S., Leong S.S., Kawinski E., Karr J.P., Rosenthal H., Chu T.M., Mirand E.A., Murphy G.P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983, 43:1809-1818.
89. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Investig. Urol. 1979, 17:16-23.
90. Chen Y., Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int. J. Cancer 2001, 91:41-45.
91. Sharrard R.M., Maitland N.J. Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines. Cell. Signal. 2007, 19:129-138.
92. Dozmorov M.G., Hurst R.E., Culkin D.J., Kropp B.P., Frank M.B., Osban J., Penning T.M., Lin H.K. Unique patterns of molecular profiling between human prostate cancer LNCaP and PC-3 cells. Prostate 2009, 69:1077-1090.
93. Krycer J.R., Brown A.J. Does changing androgen receptor status during prostate cancer development impact upon cholesterol homeostasis?. PLoS ONE 2013, 8:e54007.
94. Ettinger S.L., Sobel R., Whitmore T.G., Akbari M., Bradley D.R., Gleave M.E., Nelson C.C. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 2004, 64:2212-2221.
95. Murillo H., Huang H., Schmidt L.J., Smith D.I., Tindall D.J. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 2001, 142:4795-4805.
96. Pei H., Li L., Fridley B.L., Jenkins G.D., Kalari K.R., Lingle W., Petersen G., Lou Z., Wang L. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 2009, 16:259-266.
97. Velasco A.M., Gillis K.A., Li Y., Brown E.L., Sadler T.M., Achilleos M., Greenberger L.M., Frost P., Bai W., Zhang Y. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004, 145:3913-3924.
98. Febbo P.G., Lowenberg M., Thorner A.R., Brown M., Loda M., Golub T.R. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J. Urol. 2005, 173:1772-1777.
99. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 2004, 22:179-184.
100. Murtola T.J., Syvala H., Pennanen P., Blauer M., Solakivi T., Ylikomi T., Tammela T.L. The importance of LDL and cholesterol metabolism for prostate epithelial cell growth. PLoS One 2012, 7:e39445.
101. Twiddy A.L., Leon C.G., Wasan K.M. Cholesterol as a potential target for castration-resistant prostate cancer. Pharm. Res. 2011, 28:423-437.
102. Brown M.S., Goldstein J.L. Lowering plasma cholesterol by raising LDL receptors. N. Engl. J. Med. 1981, 305:515-517.
103. Brown A.J. Does upsizing statins have a downside?. Drug Saf. 2010, 33:435-436.
104. Bocan T.M., Ferguson E., McNally W., Uhlendorf P.D., Bak Mueller S., Dehart P., Sliskovic D.R., Roth B.D., Krause B.R., Newton R.S. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1992, 1123:133-144.
105. Sirtori C.R. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol. Ther. 1993, 60:431-459.
106. Nezasa K., Higaki K., Matsumura T., Inazawa K., Hasegawa H., Nakano M., Koike M. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab. Dispos. 2002, 30:1158-1163.
107. Solomon K.R., Freeman M.R. Do the cholesterol-lowering properties of statins affect cancer risk?. Trends Endocrinol. Metab. 2008, 19:113-121.
108. Krycer J.R., Phan L., Brown A.J. A key regulator of cholesterol homoeostasis, SREBP-2, can be targeted in prostate cancer cells with natural products. Biochem. J. 2012, 446:191-201.
109. DeBose-Boyd R.A. Feedback regulation of cholesterol synthesis: sterol-accelerated ubiquitination and degradation of HMG CoA reductase. Cell Res. 2008, 18:609-621.
110. Wong J., Quinn C.M., Brown A.J. Synthesis of the oxysterol, 24(S), 25-epoxycholesterol, parallels cholesterol production and may protect against cellular accumulation of newly-synthesized cholesterol. Lipids Health Dis. 2007, 6:10.
111. Wong J., Quinn C.M., Gelissen I.C., Brown A.J. Endogenous 24(S),25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J. Biol. Chem. 2008, 283:700-707.
112. Brown A.J. 24(S),25-epoxycholesterol: a messenger for cholesterol homeostasis. Int. J. Biochem. Cell Biol. 2009, 41:744-747.
113. Chuu C.P., Kokontis J.M., Hiipakka R.A., Liao S. Modulation of liver X receptor signaling as novel therapy for prostate cancer. J. Biomed. Sci. 2007, 14:543-553.
114. Dufour J., Viennois E., De Boussac H., Baron S., Lobaccaro J.M. Oxysterol receptors, AKT and prostate cancer. Curr. Opin. Pharmacol. 2012, 12:724-728.
115. Sen C.K., Khanna S., Roy S. Tocotrienols: Vitamin E beyond tocopherols. Life Sci. 2006, 78:2088-2098.
116. Pearce B.C., Parker R.A., Deason M.E., Qureshi A.A., Wright J.J. Hypocholesterolemic activity of synthetic and natural tocotrienols. J. Med. Chem. 1992, 35:3595-3606.
117. Parker R.A., Pearce B.C., Clark R.W., Gordon D.A., Wright J.J. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J. Biol. Chem. 1993, 268:11230-11238.
118. Song B.L., DeBose-Boyd R.A. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme a reductase stimulated by delta- and gamma-tocotrienols. J. Biol. Chem. 2006, 281:25054-25061.
119. Ling M.T., Luk S.U., Al-Ejeh F., Khanna K.K. Tocotrienol as a potential anticancer agent. Carcinogenesis 2012, 33:233-239.
120. Wada S. Cancer preventive effects of vitamin E. Curr. Pharm. Biotechnol. 2012, 13:156-164.
121. Yap W.N., Zaiden N., Luk S.Y., Lee D.T., Ling M.T., Wong Y.C., Yap Y.L. In vivo evidence of gamma-tocotrienol as a chemosensitizer in the treatment of hormone-refractory prostate cancer. Pharmacology 2010, 85:248-258.
122. Luk S.U., Yap W.N., Chiu Y.T., Lee D.T., Ma S., Lee T.K., Vasireddy R.S., Wong Y.C., Ching Y.P., Nelson C., Yap Y.L., Ling M.T. Gamma-tocotrienol as an effective agent in targeting prostate cancer stem cell-like population. Int. J. Cancer 2011, 128:2182-2191.
123. Heinonen O.P., Albanes D., Virtamo J., Taylor P.R., Huttunen J.K., Hartman A.M., Haapakoski J., Malila N., Rautalahti M., Ripatti S., Maenpaa H., Teerenhovi L., Koss L., Virolainen M., Edwards B.K. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 1998, 90:440-446.
124. Lippman S.M., Klein E.A., Goodman P.J., Lucia M.S., Thompson I.M., Ford L.G., Parnes H.L., Minasian L.M., Gaziano J.M., Hartline J.A., Parsons J.K., Bearden J.D., Crawford E.D., Goodman G.E., Claudio J., Winquist E., Cook E.D., Karp D.D., Walther P., Lieber M.M., Kristal A.R., Darke A.K., Arnold K.B., Ganz P.A., Santella R.M., Albanes D., Taylor P.R., Probstfield J.L., Jagpal T.J., Crowley J.J., Meyskens F.L., Baker L.H., Coltman C.A. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301:39-51.
125. Klein E.A., Thompson I.M., Tangen C.M., Crowley J.J., Lucia M.S., Goodman P.J., Minasian L.M., Ford L.G., Parnes H.L., Gaziano J.M., Karp D.D., Lieber M.M., Walther P.J., Klotz L., Parsons J.K., Chin J.L., Darke A.K., Lippman S.M., Goodman G.E., Meyskens F.L., Baker L.H. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2011, 306:1549-1556.
126. Kamisuki S., Mao Q., Abu-Elheiga L., Gu Z., Kugimiya A., Kwon Y., Shinohara T., Kawazoe Y., Sato S.-I., Asakura K., Choo H.-Y.P., Sakai J., Wakil S.J., Uesugi M. A small molecule that blocks fat synthesis by inhibiting the activation of SREBP. Chem. Biol. 2009, 16:882-892.
127. Krycer J.R., Brown A.J. Putative fat fighter hits the middle man. Chem. Biol. 2009, 16:798-800.
128. Masquelier M., Lundberg B., Peterson C., Vitols S. Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells. Leuk. Res. 2006, 30:136-144.
129. Ades A., Carvalho J.P., Graziani S.R., Amancio R.F., Souen J.S., Pinotti J.A., Maranhao R.C. Uptake of a cholesterol-rich emulsion by neoplastic ovarian tissues. Gynecol. Oncol. 2001, 82:84-87.
130. Hurwitz A.A., Foster B.A., Allison J.P., Greenberg N.M., Kwon E.D. The TRAMP mouse as a model for prostate cancer. Curr. Protoc. Immunol. 2001, 45:20.25.21-20.25.23.
131. Sgouros G., Yang W.H., Enmon R. Spheroids of prostate tumor cell lines. Methods Mol. Med 2003, vol. 81:79-88. Humana Press Inc., New York.
132. Ballangrud A.M., Yang W.H., Dnistrian A., Lampen N.M., Sgouros G. Growth and characterization of LNCaP prostate cancer cell spheroids. Clin. Cancer Res. 1999, 5:3171s-3176s.
133. Takagi A., Watanabe M., Ishii Y., Morita J., Hirokawa Y., Matsuzaki T., Shiraishi T. Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer. Res. 2007, 27:45-53.
134. Stewart G.D., Ross J.A., McLaren D.B., Parker C.C., Habib F.K., Riddick A.C. The relevance of a hypoxic tumour microenvironment in prostate cancer. BJU Int. 2010, 105:8-13.
135. Higgins L.H., Withers H.G., Garbens A., Love H.D., Magnoni L., Hayward S.W., Moyes C.D. Hypoxia and the metabolic phenotype of prostate cancer cells. Biochim. Biophys. Acta 2009, 1787:1433-1443.
136. Freeman M.R., Solomon K.R. Cholesterol and benign prostate disease. Differentiation 2011, 82:244-252.
137. Rhodes D.R., Yu J., Shanker K., Deshpande N., Varambally R., Ghosh D., Barrette T., Pandey A., Chinnaiyan A.M. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6.
138. Vanaja D.K., Cheville J.C., Iturria S.J., Young C.Y. Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res. 2003, 63:3877-3882.
139. Wallace T.A., Prueitt R.L., Yi M., Howe T.M., Gillespie J.W., Yfantis H.G., Stephens R.M., Caporaso N.E., Loffredo C.A., Ambs S. Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res. 2008, 68:927-936.
140. Yu Y.P., Landsittel D., Jing L., Nelson J., Ren B., Liu L., McDonald C., Thomas R., Dhir R., Finkelstein S., Michalopoulos G., Becich M., Luo J.H. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 2004, 22:2790-2799.
141. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., Reuter V., Gerald W.L. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am. J. Pathol. 2004, 164:217-227.
142. LaTulippe E., Satagopan J., Smith A., Scher H., Scardino P., Reuter V., Gerald W.L. Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res. 2002, 62:4499-4506.
143. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
144. Siperstein M.D., Fagan V.M. Deletion of the cholesterol-negative feedback system in liver tumors. Cancer Res. 1964, 24:1108-1115.
145. Tatidis L., Gruber A., Vitols S. Decreased feedback regulation of low density lipoprotein receptor activity by sterols in leukemic cells from patients with acute myelogenous leukemia. J. Lipid Res. 1997, 38:2436-2445.
146. Cerda S.R., Wilkinson J., Broitman S.A. Regulation of cholesterol synthesis in four colonic adenocarcinoma cell lines. Lipids 1995, 30:1083-1092.
147. Hentosh P., Yuh S.H., Elson C.E., Peffley D.M. Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol. Carcinog. 2001, 32:154-166.
148. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N. Engl. J. Med. 2012, 367:1792-1802.
149. Sekine Y., Demosky S.J., Stonik J.A., Furuya Y., Koike H., Suzuki K., Remaley A.T. High-density lipoprotein induces proliferation and migration of human prostate androgen-independent cancer cells by an ABCA1-dependent mechanism. Mol. Cancer Res. 2010, 8:1284-1294.
150. Freeman M.R., Solomon K.R. Cholesterol and prostate cancer. J. Cell. Biochem. 2004, 91:54-69.
151. van Meer G., de Kroon A.I. Lipid map of the mammalian cell. J. Cell Sci. 2011, 124:5-8.
152. Galea A.M., Brown A.J. Special relationship between sterols and oxygen: were sterols an adaptation to aerobic life?. Free Radic. Biol. Med. 2009, 47:880-889.
153. Inder K.L., Zheng Y.Z., Davis M.J., Moon H., Loo D., Nguyen H., Clements J.A., Parton R.G., Foster L.J., Hill M.M. Expression of PTRF in PC-3 cells modulates cholesterol dynamics and the actin cytoskeleton impacting secretion pathways. Mol. Cell. Proteomics 2012, 11. (M111 012245).
154. Ronquist G., Brody I. The prostasome: its secretion and function in man. Biochim. Biophys. Acta 1985, 822:203-218.
155. Ronquist G., Nilsson B.O. The Janus-faced nature of prostasomes: their pluripotency favours the normal reproductive process and malignant prostate growth. Prostate Cancer Prostatic Dis 2004, 7:21-31.
156. Sahlen G., Ahlander A., Frost A., Ronquist G., Norlen B.J., Nilsson B.O. Prostasomes are secreted from poorly differentiated cells of prostate cancer metastases. Prostate 2004, 61:291-297.
157. Tavoosidana G., Ronquist G., Darmanis S., Yan J., Carlsson L., Wu D., Conze T., Ek P., Semjonow A., Eltze E., Larsson A., Landegren U.D., Kamali-Moghaddam M. Multiple recognition assay reveals prostasomes as promising plasma biomarkers for prostate cancer. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:8809-8814.
158. Arvidson G., Ronquist G., Wikander G., Ojteg A.C. Human prostasome membranes exhibit very high cholesterol/phospholipid ratios yielding high molecular ordering. Biochim. Biophys. Acta 1989, 984:167-173.
159. Carlsson L., Nilsson O., Larsson A., Stridsberg M., Sahlen G., Ronquist G. Characteristics of human prostasomes isolated from three different sources. Prostate 2003, 54:322-330.
160. Carlini E., Palmerini C.A., Cosmi E.V., Arienti G. Fusion of sperm with prostasomes: effects on membrane fluidity. Arch. Biochem. Biophys. 1997, 343:6-12.
161. Cross N.L., Mahasreshti P. Prostasome fraction of human seminal plasma prevents sperm from becoming acrosomally responsive to the agonist progesterone. Arch. Androl. 1997, 39:39-44.
162. Arienti G., Carlini E., Polci A., Cosmi E.V., Palmerini C.A. Fatty acid pattern of human prostasome lipid. Arch. Biochem. Biophys. 1998, 358:391-395.
163. Llorente A., van Deurs B., Sandvig K. Cholesterol regulates prostasome release from secretory lysosomes in PC-3 human prostate cancer cells. Eur. J. Cell Biol. 2007, 86:405-415.
164. Aberg M., Johnell M., Wickstrom M., Widunder A., Siegbahn A. Simvastatin reduces the production of prothrombotic prostasomes in human prostate cancer cells. Thromb. Haemost. 2008, 100:655-662.
165. Pagler T.A., Rhode S., Neuhofer A., Laggner H., Strobl W., Hinterndorfer C., Volf I., Pavelka M., Eckhardt E.R., van der Westhuyzen D.R., Schutz G.J., Stangl H. SR-BI-mediated high density lipoprotein (HDL) endocytosis leads to HDL resecretion facilitating cholesterol efflux. J. Biol. Chem. 2006, 281:11193-11204.
166. Swinnen J.V., Roskams T., Joniau S., Van Poppel H., Oyen R., Baert L., Heyns W., Verhoeven G. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int. J. Cancer 2002, 98:19-22.
167. Rossi S., Graner E., Febbo P., Weinstein L., Bhattacharya N., Onody T., Bubley G., Balk S., Loda M. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol. Cancer Res. 2003, 1:707-715.
168. Pizer E.S., Pflug B.R., Bova G.S., Han W.F., Udan M.S., Nelson J.B. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression. Prostate 2001, 47:102-110.
169. Swinnen J.V., Brusselmans K., Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:358-365.
170. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7:763-777.
171. Hochachka P.W., Rupert J.L., Goldenberg L., Gleave M., Kozlowski P. Going malignant: the hypoxia-cancer connection in the prostate. Bioessays 2002, 24:749-757.
172. Costello L.C., Franklin R.B. Concepts of citrate production and secretion by prostate: 2. Hormonal relationships in normal and neoplastic prostate. Prostate 1991, 19:181-205.
173. Costello L.C., Franklin R.B. Concepts of citrate production and secretion by prostate. 1. Metabolic relationships. Prostate 1991, 18:25-46.
174. Moon J.S., Jin W.J., Kwak J.H., Kim H.J., Yun M.J., Kim J.W., Park S.W., Kim K.S. Androgen stimulates glycolysis for de novo lipid synthesis by increasing the activities of hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2 in prostate cancer cells. Biochem. J. 2011, 433:225-233.
175. Pan J.G., Mak T.W. Metabolic targeting as an anticancer strategy: dawn of a new era?. Sci. STKE 2007, 2007:e14.
176. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
177. Vander Heiden M.G., Cantley L.C., Thompson C.B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009, 324:1029-1033.
178. Gill S., Stevenson J., Kristiana I., Brown A.J. Cholesterol-dependent degradation of squalene monooxygenase, a control point in cholesterol synthesis beyond HMG-CoA reductase. Cell Metab. 2011, 13:260-273.